Iqvia Hldgs Inc Stock Price, News & Analysis

IQVIA Holdings Inc. reported a first-quarter 2023 revenue of $3,652 million, a 2.4% increase year-over-year. GAAP net income stood at $289 million, with diluted earnings per share of $1.53. Adjusted EBITDA reached $851 million, up 10.4% year-over-year. R&D Solutions saw a significant growth in booked contracts, totaling $2.6 billion, leading to a book-to-bill ratio of 1.28x. The contracted backlog for R&D Solutions reached $27.9 billion, a 10.1% year-over-year increase. The company reaffirmed its full-year 2023 guidance, anticipating revenue between $15,150 million and $15,400 million.

IQVIA (NYSE:IQV) has been recognized as a Leader in Customer Experience Platforms (CXP) by Everest Group for its Orchestrated Customer Engagement (OCE) platform. This Salesforce-based solution provides a comprehensive suite of capabilities aimed at enhancing customer engagement for life sciences companies. The OCE platform is praised for its efficiency, actionable analytics, and industry-specific best practices, making it a preferred choice among biopharma clients. Everest Group highlights IQVIA's strong customer engagement capabilities as a key differentiator in a competitive landscape. The recognition underscores IQVIA's commitment to delivering innovative analytics and technology solutions that support clinical development and commercialization in the life sciences sector.

IQVIA Holdings Inc. (NYSE:IQV) is set to announce its first-quarter 2023 financial results on April 27, 2023, before market open. The management team will host a conference call and webcast at 9:00 a.m. Eastern Time to discuss these results. Investors can access the earnings release and financial data on the IQVIA Investor Relations website. To join the live event, participants must register in advance through a provided link, receiving confirmation with call details afterward. A replay of the webcast will be available two hours post-event. With around 86,000 employees across 100 countries, IQVIA specializes in advanced analytics, technology, and clinical research services for the life sciences sector, aiming to enhance healthcare outcomes through data-driven insights.

In 2022, global clinical trial activity showed resilience with a 1% decline in non-COVID trials compared to 2021, while COVID-19 trials fell from 10% to 6% of total trials. A report from the IQVIA Institute revealed an 8% increase in non-COVID trial activity from 2019 levels, along with a 27% rise in clinical development productivity, marking a reversal of a 10-year downward trend. Total R&D spending by the largest pharmaceutical companies reached a record $138 billion, up 1.7% from 2021. Despite positive trends, there is concern over declining representation of Black/African American and Hispanic patients in clinical trials.

IQVIA Holdings Inc. (NYSE:IQV) has announced that Ron Bruehlman, the executive vice president and chief financial officer, will present at the Barclays Global Healthcare Conference in Miami, FL on Wednesday, March 15, 2023, at 9:30 a.m. ET. A live audio webcast of the presentation will be accessible via the IQVIA Investor Relations website, with a replay available later the same day. IQVIA is recognized for its advanced analytics, technology solutions, and clinical research services, operating in over 100 countries and employing approximately 86,000 individuals.

IQVIA has released its 2022 Environmental, Social, and Governance (ESG) Report, highlighting its commitment to environmental sustainability and public health improvement. The report details progress towards achieving net-zero greenhouse gas emissions, including a 22% reduction in market-based emissions per employee. Employee engagement remains strong, with over 80% of staff feeling aligned with IQVIA's mission. The company also maintained its diversity efforts, with women representing 60% of its workforce. Additionally, IQVIA was recognized on FORTUNE’s World's Most Admired Companies™ list for the sixth consecutive year, ranking first in multiple categories.